| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Mesenchymal stem cells (MSCs) have been reported to be a valuable cell source in cell therapy, and bone marrow (BM) represents a major source of MSCs; however, there are several limitations when using BM-MSCs, including inadequate cell numbers, invasiveness and donor site morbidity. Recently, several studies have shown that MSCs can be easily isolated from human fetal membrane (FM), and a large amount of cells can be obtained. We thus examined the therapeutic effects of transplantation of human FM-derived MSCs (hFM-MSCs) in dextran sulfate sodium (DSS)-induced colitis in rats.
Transplantation of hFM-MSCs provided significant improvement in a rat model of severe colitis, possibly through inhibition of monocyte/macrophage activity. FM-MSC would be considered as a new cell source for the treatment of severe colitis.
|
